SAT0047 Purine metabolism and antioxidant system in osteoarthritis

Abstract

= 3482) vs. rofecoxib (n = 6290); and, 1.31 (0.86, 2.01) when comparing non-naproxen NSAIDs or placebo (n = 6017) vs. rofecoxib (n = 7675). Conclusion (1) The risk of sustaining a thrombotic cardiovascular event was similar in patients treated with rofecoxib, placebo, or non-selective NSAIDs without sustained effects on platelet function and, (2) the risk of sustaining a thrombotic cardiovascular event was reduced in patients treated with naproxen compared to rofecoxib. This reduction in events on naproxen is likely due to its ability to maintain near complete inhibition of platelet function throughout its dosing interval.